ONCT - Oncternal Therapeutics Reports Patient Death In Mid-Stage Blood Cancer Study Treated With Second Dose Level | Benzinga
Oncternal Therapeutics Inc (NASDAQ: ONCT) updated the status of a recent study involving a treatment for relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR-T treatment.
The dose-escalation/dose-expansion Phase 1/2 Study ONCT-808-101 evaluates the company's ROR1-targeting autologous CAR T cell therapy ONCT-808.
At the initial dose of 1x106 CAR T cells per kg, two ...